Supernus Pharmaceuticals Net Income 2011-2024 | SUPN
Supernus Pharmaceuticals net income from 2011 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Supernus Pharmaceuticals Annual Net Income
(Millions of US $) |
| 2023 |
$1 |
| 2022 |
$61 |
| 2021 |
$53 |
| 2020 |
$127 |
| 2019 |
$113 |
| 2018 |
$111 |
| 2017 |
$57 |
| 2016 |
$91 |
| 2015 |
$14 |
| 2014 |
$-11 |
| 2013 |
$-92 |
| 2012 |
$-47 |
| 2011 |
$50 |
| 2010 |
$-42 |
Supernus Pharmaceuticals Quarterly Net Income
(Millions of US $) |
| 2024-09-30 |
$38 |
| 2024-06-30 |
$20 |
| 2024-03-31 |
$0 |
| 2023-12-31 |
$1 |
| 2023-09-30 |
$-16 |
| 2023-06-30 |
$-1 |
| 2023-03-31 |
$17 |
| 2022-12-31 |
$25 |
| 2022-09-30 |
$2 |
| 2022-06-30 |
$8 |
| 2022-03-31 |
$26 |
| 2021-12-31 |
$2 |
| 2021-09-30 |
$22 |
| 2021-06-30 |
$24 |
| 2021-03-31 |
$6 |
| 2020-12-31 |
$31 |
| 2020-09-30 |
$40 |
| 2020-06-30 |
$35 |
| 2020-03-31 |
$22 |
| 2019-12-31 |
$33 |
| 2019-09-30 |
$29 |
| 2019-06-30 |
$33 |
| 2019-03-31 |
$18 |
| 2018-12-31 |
$26 |
| 2018-09-30 |
$28 |
| 2018-06-30 |
$31 |
| 2018-03-31 |
$26 |
| 2017-12-31 |
$14 |
| 2017-09-30 |
$16 |
| 2017-06-30 |
$17 |
| 2017-03-31 |
$10 |
| 2016-12-31 |
$14 |
| 2016-09-30 |
$62 |
| 2016-06-30 |
$10 |
| 2016-03-31 |
$5 |
| 2015-12-31 |
$7 |
| 2015-09-30 |
$4 |
| 2015-06-30 |
$2 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$4 |
| 2014-09-30 |
$-2 |
| 2014-06-30 |
$3 |
| 2014-03-31 |
$-16 |
| 2013-12-31 |
$-22 |
| 2013-09-30 |
$-24 |
| 2013-06-30 |
$-27 |
| 2013-03-31 |
$-18 |
| 2012-12-31 |
$-14 |
| 2012-09-30 |
$-13 |
| 2012-06-30 |
$-10 |
| 2012-03-31 |
$-10 |
| 2011-12-31 |
$82 |
| 2011-09-30 |
$-11 |
| 2011-06-30 |
$-8 |
| 2011-03-31 |
$-12 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.975B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
